The effectiveness of boosters against Covid-19 will likely decline in the next few months and people may need another shot in the fall by 2022, said Stephane Bancel, Chief Executive Officer of Moderna, on Thursday at a health conference organized by Goldman Sachs.
Bancel said the company is working on a vaccine candidate tailored for the Omicron variant of the coronavirus but is unlikely to be available in the next two months.
“I still think we’ll need boosters in Fall ’22 and later,” said Bancel.
Separately, on Friday Food and Drug Administration shortened the waiting time for the third dose of the Moderna Covid vaccine after the second vaccination to five instead of six months. The FDA’s amended approval for the Moderna vaccine comes just days after the Centers for Disease Control and Prevention recommended people to receive a booster dose of Pfizer five months after the first series of two doses.
Bancels comment on the need for a fourth shot follows Israeli Prime Minister Naftali Bennett cite a study on Tuesday that a fourth dose of the Covid-19 vaccine increased antibodies five-fold a week after the injection.
Moderna, which benefits from repeat vaccinations, said in its third quarter earnings results that sales in the commercial booster market in the United States could reach $ 2 billion in 2022.